Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).
复制标题
卫生保健专业人员在接种两剂SARS-CoV-2mRNA疫苗(BNT162b2)后的早期抗体反应。
DOI：
10.1016/j.cmi.2021.05.004
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Douxfils J
中科院分区：
文献类型：
--
作者：
Favresse J;Bayart JL;Mullier F;Dogné JM;Closset M;Douxfils J
迄今为止，关于两剂BNT162b2后免疫反应的数据有限。先前感染的个体被排除在关键临床试验之外，这一人群的最佳剂量方案尚未得到明确研究。CRO-VAX HCP研究旨在调查接受两剂BNT162b2 mRNA冠状病毒病2019 （COVID-19）疫苗的卫生保健专业人员人群的早期抗体反应。CRO-VAX HCP研究是一项在比利时多个地点进行的多中心、前瞻性、干预性研究。该研究包括231名卫生保健专业志愿者，他们接受了BNT162b2 mRNA COVID-19疫苗的两剂方案。其中，73人以前感染过严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)， 158人未感染且血清阴性。第一组在基线和2、4、7、10、14、21和28天后采集血样。第二组分别在基线、14天和28天后采集样本。在不同时间点对所有个体的SARS-CoV-2核衣壳抗体和刺突蛋白S1亚基受体结合域进行检测。在未感染的个体中，95.5% （95% CI 91.0%-98.2%）在14天后产生抗刺突抗体，第二次注射后抗体滴度上升24.9倍（95% CI 21.4%-28.9%）。在先前感染的个体中，抗体反应在7天后达到峰值（即6347 U/mL），第二次剂量没有导致显着更高的抗体滴度（即8856-11 911 U/mL）。抗体滴度在以前感染的个体中较高。该研究支持单剂量BNT162b2对先前感染的个体足够的概念。
Data on the immune response after two doses of BNT162b2 are so far limited. Previously infected individuals were excluded from pivotal clinical trials and the optimum dose regimen in this population has not been clearly studied. The CRO-VAX HCP study aims to investigate the early antibody response in a population of health-care professionals having received two doses of the BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine. The CRO-VAX HCP study is a multicentre, prospective, interventional study conducted in several sites in Belgium. The study included 231 health-care professional volunteers who received the two-dose regimen of the BNT162b2 mRNA COVID-19 vaccine. Of these, 73 were previously infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 158 were uninfected and seronegative. In the first group, blood samples were collected at baseline and after 2, 4, 7, 10, 14, 21 and 28 days. In the second group, samples were obtained at baseline and after 14 and 28 days. Antibodies against the SARS-CoV-2 nucleocapsid and the receptor binding domain of the S1 subunit of the spike protein were measured in all individuals at different time-points. In uninfected individuals, 95.5% (95% CI 91.0%–98.2%) developed anti-spike antibodies after 14 days and a 24.9-fold rise (95% CI 21.4%–28.9%) in antibody titre was observed after the second dose. In previously infected individuals, peak antibody response was reached after 7 days (i.e. 6347 U/mL) and the second dose did not lead to significantly higher antibody titres (i.e. 8856–11 911 U/mL). Antibody titres were higher in previously infected individuals. This study supports the concept that a single dose of BNT162b2 would be sufficient in previously infected individuals.
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
抗SARS-COV-2抗体的持久性取决于分析试剂盒：感染后长达10个月的报告。
影响因子：
4.5
作者：
Favresse J;Eucher C;Elsen M;Gillot C;Van Eeckhoudt S;Dogné JM;Douxfils J
通讯作者：
Douxfils J
DOI：
10.1056/nejmoa2027906
发表时间：
2020-12-17
期刊：
The New England journal of medicine
影响因子：
--
作者：
Walsh EE;Frenck RW Jr;Falsey AR;Kitchin N;Absalon J;Gurtman A;Lockhart S;Neuzil K;Mulligan MJ;Bailey R;Swanson KA;Li P;Koury K;Kalina W;Cooper D;Fontes-Garfias C;Shi PY;Türeci Ö;Tompkins KR;Lyke KE;Raabe V;Dormitzer PR;Jansen KU;Şahin U;Gruber WC
通讯作者：
Gruber WC